A human laboratory study of mifepristone as a novel treatment for alcohol use disorder

Advances in the neurobiology of alcohol use disorder (AUD) have highlighted an association between dysregulation of central stress systems and risk of drinking relapse during protracted abstinence. Potential treatment targets include the hypothalamic-pituitary-adrenal (HPA) axis and impairment in glucocorticoid receptor (GR) feedback and activity. We hypothesized that treatment with the mixed GR/progesterone receptor anatagonist, mifepristone, would reduce alcohol craving and drinking in non treatment-seeking outpatient alcoholics relative to placebo.
Source: Alcohol - Category: Addiction Authors: Source Type: research